For the quarter ending 2025-09-30, JAGX had $1,320K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net comprehensive loss | -9,781 | -21,441 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | -2,310 | -2,411 |
| Loss (gain) on extinguishment of debt | 0 | -1,822 |
| Depreciation and amortization expenses | 479 | 957 |
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 135 | 580 |
| Amortization of operating lease - right-of-use asset | 78 | 145 |
| Share in joint venture's loss | -45 | -75 |
| Accounts receivable | 264 | -354 |
| Other receivable | -76 | 13 |
| Inventory | -91 | 374 |
| Prepaid expenses and other current assets | 84 | 775 |
| Other assets | -2 | -106 |
| Accounts payable | 1,812 | 1,285 |
| Accrued liabilities | 528 | 1,581 |
| Deferred revenue | -43 | -85 |
| Operating lease liability | -73 | -137 |
| Total cash used in operating activities | -4,689 | -13,509 |
| Purchase of furniture and fixtures | 54 | - |
| Proceeds from issuance of shares to third party investors | - | 1,309 |
| Total cash used in investing activity | -54 | - |
| Proceeds from issuance of shares in at the market offering, net of issuance and offering costs of 161 and 127 in 2025 and 2024, respectively | 3,081 | 3,250 |
| Proceeds from convertible notes | 0 | 3,445 |
| Proceeds from issuance of preferred shares in pipe financing, net of issuance cost | 2,377 | - |
| Proceeds from issuance of common shares/gross proceeds from combined offerings-HCWInvestors | 1,309 | - |
| Proceeds from issuance of common shares/gross proceeds from combined offerings-Brown Stone Capital Limited | 1,000 | - |
| Repayment of insurance financing | 169 | 313 |
| Payment of tempesta note | 0 | 50 |
| Payment of convertible notes | 30 | 20 |
| Total cash provided by financing activities | 6,259 | 7,621 |
| Effects of foreign exchange rate changes on assets and liabilities | -196 | 93 |
| Net increase (decrease) in cash | 1,320 | -5,795 |
| Cash and cash equivalents at beginning of period | 8,002 | - |
| Cash and cash equivalents at end of period | 3,527 | - |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)